- Home
- DNMX vs FENC Comparison
DNMX vs FENC Comparison
Compare DNMX & FENC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
N/A
HOLD
Current Price
$7.57
Company Overview
Basic Information| Metric | DNMX | FENC |
|---|---|---|
| Founded | 2025 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Blank Checks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 265.4M | 276.3M |
| IPO Year | 2025 | 2001 |
Fundamental Metrics
Financial Performance| Metric | DNMX | FENC |
|---|---|---|
| Price | $9.88 | $7.57 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $13.50 |
| AVG Volume (30 Days) | 125.9K | ★ 184.9K |
| Earning Date | 01-01-0001 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $38,790,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $70.97 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $9.87 | $4.68 |
| 52 Week High | $9.96 | $9.92 |
Technical Indicators
Market Signals| Indicator | DNMX | FENC |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 46.84 |
| Support Level | N/A | $7.35 |
| Resistance Level | N/A | $7.80 |
| Average True Range (ATR) | 0.00 | 0.34 |
| MACD | 0.00 | -0.00 |
| Stochastic Oscillator | 0.00 | 29.81 |
Price Performance
Historical Comparison DNMX
FENC
About DNMX Dynamix Corporation III Class A Ordinary Shares
Dynamix Corp III is a a blank check company incorporated as a Cayman Islands exempted company and incorporated for the purpose of effecting a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses.
About FENC Fennec Pharmaceuticals Inc.
Fennec Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. Its product candidate is PEDMARK which is sodium thiosulfate in a novel formulation for the prevention of cisplatin-induced hearing loss, or ototoxicity in children. The company principally operates in the United States.